Abdel-wahab, Omar

Publications

Sort by

Co-Author Network

selected publications

DNA methylation disruption reshapes the hematopoietic differentiation landscape. Nature genetics. 2020 Academic Article GET IT
Times cited: 101
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. The Journal of clinical investigation. 2020 Academic Article GET IT
Times cited: 113
Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Academic Article GET IT
Times cited: 165
Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900. Haematologica. 2018 Letter GET IT
Times cited: 4
ProteomeGenerator: A Framework for Comprehensive Proteomics Based on de Novo Transcriptome Assembly and High-Accuracy Peptide Mass Spectral Matching. Journal of proteome research. 2018 Academic Article GET IT
Times cited: 19
Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene U2af1. Proceedings of the National Academy of Sciences of the United States of America. 2018 Academic Article GET IT
Times cited: 46
Widespread intronic polyadenylation inactivates tumour suppressor genes in leukaemia. Nature. 2018 Academic Article GET IT
Times cited: 124
KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function. Oncogene. 2018 Academic Article GET IT
Times cited: 72
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. JAMA oncology. 2018 Academic Article GET IT
Times cited: 216
The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations. Molecular cell. 2018 Academic Article GET IT
Times cited: 150
Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. Cell. 2017 Academic Article GET IT
Times cited: 435
Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. Pediatric blood & cancer. 2017 Academic Article GET IT
Times cited: 14
High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood. 2017 Academic Article GET IT
Times cited: 86
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia. 2017 Academic Article GET IT
Times cited: 43
Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood. 2017 Review GET IT
Times cited: 135
Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood. 2017 Academic Article GET IT
Times cited: 60
Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood. 2017 Academic Article GET IT
Times cited: 75
ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nature communications. 2017 Academic Article GET IT
Times cited: 44
Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1. PloS one. 2017 Academic Article GET IT
Times cited: 18
Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms. Hematology/oncology clinics of North America. 2017 Review GET IT
Times cited: 15
Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood. 2017 Academic Article GET IT
Times cited: 105
HMG-CoA synthase 1 is a synthetic lethal partner of BRAF^V600E in human cancers. The Journal of biological chemistry. 2017 Academic Article GET IT
Times cited: 25
Splicing factor mutations in MDS RARS and MDS/MPN-RS-T. International journal of hematology. 2017 Review GET IT
Times cited: 16
Modeling CBL activating mutations in vivo. Blood. 2017 Comment GET IT
How do messenger RNA splicing alterations drive myelodysplasia?. Blood. 2017 Review GET IT
Times cited: 25
Partial loss of genes might open therapeutic window. eLife. 2017 Comment GET IT
Times cited: 1
The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood advances. 2017 Academic Article GET IT
Times cited: 120
Histiocytoses: emerging neoplasia behind inflammation. The Lancet. Oncology. 2017 Review GET IT
Times cited: 143
Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. Cell metabolism. 2017 Academic Article GET IT
Times cited: 93
Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget. 2016 Academic Article GET IT
Times cited: 43
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2016 Conference Paper GET IT
Times cited: 154
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nature medicine. 2016 Academic Article GET IT
Times cited: 169
Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 20
The Role of Additional Sex Combs-Like Proteins in Cancer. Cold Spring Harbor perspectives in medicine. 2016 Review GET IT
Times cited: 42
Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2016 Academic Article GET IT
Times cited: 9
Modeling SF3B1 Mutations in Cancer: Advances, Challenges, and Opportunities. Cancer cell. 2016 Comment GET IT
Times cited: 18
Therapeutic targeting of splicing in cancer. Nature medicine. 2016 Review GET IT
Times cited: 349
Defining risk in MDS over time. Blood. 2016 Comment GET IT
Times cited: 2
Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease. Blood. 2016 Letter GET IT
Times cited: 21
EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. Cancer cell. 2016 Academic Article GET IT
Times cited: 166
Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester disease. Orphanet journal of rare diseases. 2016 Letter GET IT
Times cited: 19
Emerging concepts of epigenetic dysregulation in hematological malignancies. Nature immunology. 2016 Review GET IT
Times cited: 66
Histiocytic neoplasms in the era of personalized genomic medicine. Current opinion in hematology. 2016 Review GET IT
Times cited: 32
ASXL1 plays an important role in erythropoiesis. Scientific reports. 2016 Academic Article GET IT
Times cited: 29
Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia. British journal of haematology. 2016 Academic Article GET IT
Times cited: 26
Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development. Cancer cell. 2016 Academic Article GET IT
Times cited: 104
RNA splicing factors as oncoproteins and tumour suppressors. Nature reviews. Cancer. 2016 Review GET IT
Times cited: 422
Erratum: Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nature medicine. 2016 Academic Article GET IT
Times cited: 4
Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nature medicine. 2016 Letter GET IT
Times cited: 7
Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. Leukemia & lymphoma. 2016 Review GET IT
Times cited: 5
Loss of Asxl1 Alters Self-Renewal and Cell Fate of Bone Marrow Stromal Cell, Leading to Bohring-Opitz-like Syndrome in Mice. Stem cell reports. 2016 Academic Article GET IT
Times cited: 16
Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nature medicine. 2016 Academic Article GET IT
Times cited: 250
Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis. Genes & development. 2016 Review GET IT
Times cited: 76
Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood. 2016 Academic Article GET IT
Times cited: 162
Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood. 2016 Academic Article GET IT
Times cited: 208
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016 Review GET IT
Times cited: 820
MSI2 is required for maintaining activated myelodysplastic syndrome stem cells. Nature communications. 2016 Academic Article GET IT
Times cited: 24
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016 Academic Article GET IT
Times cited: 102
Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells. Leukemia. 2015 Academic Article GET IT
Times cited: 53
Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing. eLife. 2015 Academic Article GET IT
Times cited: 96
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nature medicine. 2015 Academic Article GET IT
Times cited: 118
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer discovery. 2015 Academic Article GET IT
Times cited: 313
Loss of BAP1 function leads to EZH2-dependent transformation. Nature medicine. 2015 Academic Article GET IT
Times cited: 253
BET inhibitor resistance emerges from leukaemia stem cells. Nature. 2015 Academic Article GET IT
Times cited: 390
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 245
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer cell. 2015 Academic Article GET IT
Times cited: 307
Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia. Leukemia. 2015 Letter GET IT
Times cited: 70
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Molecular cell. 2015 Academic Article GET IT
Times cited: 107
Hairy cell leukemia: update and current therapeutic approach. Current opinion in hematology. 2015 Review GET IT
Times cited: 6
Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center. British journal of haematology. 2015 Academic Article GET IT
Times cited: 13
Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21). Leukemia & lymphoma. 2015 Letter GET IT
Times cited: 15
SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. Cancer cell. 2015 Academic Article GET IT
Times cited: 382
Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. The Journal of clinical investigation. 2015 Academic Article GET IT
Times cited: 145
Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. Leukemia. 2015 Letter GET IT
Times cited: 46
Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition. Leukemia. 2015 Academic Article GET IT
Times cited: 41
JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer discovery. 2015 Academic Article GET IT
Times cited: 212
DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell reports. 2014 Academic Article GET IT
Times cited: 206
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proceedings of the National Academy of Sciences of the United States of America. 2014 Academic Article GET IT
Times cited: 209
Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leukemia & lymphoma. 2014 Review GET IT
Times cited: 3
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer discovery. 2014 Academic Article GET IT
Times cited: 105
SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS. Leukemia. 2014 Academic Article GET IT
Times cited: 58
BRAF-mutant hematopoietic malignancies. Oncotarget. 2014 Editorial Article GET IT
Times cited: 3
The mutational landscape of paroxysmal nocturnal hemoglobinuria revealed: new insights into clonal dominance. The Journal of clinical investigation. 2014 Comment GET IT
Times cited: 12
Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood. 2014 Academic Article GET IT
Times cited: 176
Somatic alterations and dysregulation of epigenetic modifiers in cancers. Biochemical and biophysical research communications. 2014 Review GET IT
Times cited: 27
Femoral bone marrow aspiration in live mice. Journal of visualized experiments : JoVE. 2014 Academic Article GET IT
Times cited: 12
Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. Blood. 2014 Academic Article GET IT
Times cited: 102
Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Molecular cancer therapeutics. 2014 Academic Article GET IT
Times cited: 45
Recent discoveries in molecular characterization of acute myeloid leukemia. Current hematologic malignancy reports. 2014 Review GET IT
Times cited: 19
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Science translational medicine. 2014 Academic Article GET IT
Times cited: 98
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. 2014 GET IT
Times cited: 385
Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms. Haematologica. 2014 Editorial Article GET IT
Times cited: 5
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014 Academic Article GET IT
Times cited: 310
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. 2014 GET IT
Times cited: 67
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes & development. 2014 Academic Article GET IT
Times cited: 62
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leukemia & lymphoma. 2014 Review GET IT
Times cited: 18
Collaborating constitutive and somatic genetic events in myeloid malignancies: ASXL1 mutations in patients with germline GATA2 mutations. Haematologica. 2014 Editorial Article GET IT
Times cited: 35
The importance of subclonal genetic events in MDS. Blood. 2013 Comment GET IT
Times cited: 8
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. The Journal of experimental medicine. 2013 Academic Article GET IT
Times cited: 254
Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations. The Journal of clinical investigation. 2013 Academic Article GET IT
Times cited: 54
Detection of an NRAS mutation in Erdheim-Chester disease. Blood. 2013 Letter GET IT
Times cited: 52
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 2013 Academic Article GET IT
Times cited: 96
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood. 2013 Academic Article GET IT
Times cited: 162
Toll-like receptor alterations in myelodysplastic syndrome. Leukemia. 2013 Academic Article GET IT
Times cited: 131
Importance of genetics in the clinical management of chronic myelomonocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Editorial Article GET IT
Times cited: 9
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer cell. 2013 Academic Article GET IT
Times cited: 608
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood. 2013 Review GET IT
Times cited: 206
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood. 2013 Academic Article GET IT
Times cited: 159
GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013 Academic Article GET IT
Times cited: 116
Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression. Cancer cell. 2013 Academic Article GET IT
Times cited: 96
Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia. Nature medicine. 2013 Academic Article GET IT
Times cited: 175
Notch pathway activation targets AML-initiating cell homeostasis and differentiation. The Journal of experimental medicine. 2013 Academic Article GET IT
Times cited: 127
Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica. 2013 Academic Article GET IT
Times cited: 94
HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. The Journal of experimental medicine. 2013 Academic Article GET IT
Times cited: 40
Focus on the epigenome in the myeloproliferative neoplasms. Hematology. American Society of Hematology. Education Program. 2013 Review GET IT
Times cited: 11
The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. The Journal of biological chemistry. 2012 Academic Article GET IT
Times cited: 125
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica. 2012 Academic Article GET IT
Times cited: 56
Progression of RAS-mutant leukemia during RAF inhibitor treatment. 2012 GET IT
Times cited: 197
Translocation t(11;17) in de novo myelodysplastic syndrome not associated with acute myeloid or acute promyelocytic leukemia. 2012 GET IT
Times cited: 3
Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leukemia research. 2012 Academic Article GET IT
Times cited: 27
The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics. Leukemia. 2012 Review GET IT
Times cited: 73
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. European urology. 2012 Academic Article GET IT
Times cited: 173
Epigenetic alterations in hematopoietic malignancies. International journal of hematology. 2012 Review GET IT
Times cited: 45
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature genetics. 2012 Academic Article GET IT
Times cited: 614
Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer. British journal of cancer. 2012 Academic Article GET IT
Times cited: 88
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012 Academic Article GET IT
Times cited: 281
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. 2012 GET IT
Times cited: 43
Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms. Hematology/oncology clinics of North America. 2012 Review GET IT
Times cited: 23
The role of mutations in epigenetic regulators in myeloid malignancies. Nature reviews. Cancer. 2012 Review GET IT
Times cited: 562
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer cell. 2012 Academic Article GET IT
Times cited: 455
Refining the prognostic importance of the diversity of FLT3 internal tandem duplications. Leukemia & lymphoma. 2012 Comment GET IT
Times cited: 1
Loss of the tumor suppressor BAP1 causes myeloid transformation. Science (New York, N.Y.). 2012 Academic Article GET IT
Times cited: 307
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 383
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood. 2012 Academic Article GET IT
Times cited: 78
2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. Leukemia & lymphoma. 2012 Letter GET IT
Times cited: 19
Molecular genetics of acute myeloid leukemia: clinical implications and opportunities for integrating genomics into clinical practice. Hematology (Amsterdam, Netherlands). 2012 Academic Article GET IT
Times cited: 7
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. American journal of hematology. 2012 Conference Paper GET IT
Times cited: 14
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012 Academic Article GET IT
Times cited: 179
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. The New England journal of medicine. 2012 Academic Article GET IT
Times cited: 1497
Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms. Current hematologic malignancy reports. 2012 Review GET IT
Times cited: 7
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012 Academic Article GET IT
Times cited: 1461
Interpreting new molecular genetics in myelodysplastic syndromes. Hematology. American Society of Hematology. Education Program. 2012 Review GET IT
Times cited: 33
Molecular alterations underlying eosinophilic and mast cell malignancies. Discovery medicine. 2011 Review GET IT
Times cited: 7
Clinical implications of novel mutations in epigenetic modifiers in AML. Hematology/oncology clinics of North America. 2011 Review GET IT
Times cited: 40
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia. 2011 Academic Article GET IT
Times cited: 72
FISHing for TET2: Utility of FISH for TET2 deletions detection in clinical samples. Leukemia research. 2011 Editorial Article GET IT
Times cited: 1
Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen. Blood. 2011 Academic Article GET IT
Times cited: 74
TET family proteins and their role in stem cell differentiation and transformation. Cell stem cell. 2011 Review GET IT
Times cited: 190
The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity. Leukemia. 2011 Academic Article GET IT
Times cited: 31
Clinical effect of point mutations in myelodysplastic syndromes. The New England journal of medicine. 2011 Academic Article GET IT
Times cited: 1241
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer cell. 2011 Academic Article GET IT
Times cited: 970
Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Advances in hematology. 2011 Academic Article GET IT
Times cited: 68
Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML. Blood. 2011 Academic Article GET IT
Times cited: 34
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 2011 Academic Article GET IT
Times cited: 302
Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. The Journal of biological chemistry. 2011 Academic Article GET IT
Times cited: 39
DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia. 2011 Letter GET IT
Times cited: 117
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia. 2011 Letter GET IT
Times cited: 177
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood cancer journal. 2011 Academic Article GET IT
Times cited: 11
Genetics of the myeloproliferative neoplasms. Current opinion in hematology. 2011 Review GET IT
Times cited: 40
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer cell. 2011 Academic Article GET IT
Times cited: 196
ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition. Haematologica. 2010 Letter GET IT
Times cited: 18
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer cell. 2010 Academic Article GET IT
Times cited: 2085
PHF6 mutations in adult acute myeloid leukemia. Leukemia. 2010 Academic Article GET IT
Times cited: 36
A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proceedings of the National Academy of Sciences of the United States of America. 2010 Academic Article GET IT
Times cited: 95
The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer cell. 2010 Academic Article GET IT
Times cited: 224
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. The Journal of clinical investigation. 2010 Academic Article GET IT
Times cited: 152
Recent advances in the treatment of acute myeloid leukemia. F1000 medicine reports. 2010 Academic Article GET IT
Times cited: 1336
The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia. 2010 Letter GET IT
Times cited: 64
Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera. Blood. 2010 Academic Article GET IT
Times cited: 41
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010 Academic Article GET IT
Times cited: 263
Metabolism and the leukemic stem cell. The Journal of experimental medicine. 2010 Comment GET IT
Times cited: 65
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer cell. 2010 Academic Article GET IT
Times cited: 1554
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood. 2010 Academic Article GET IT
Times cited: 64
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer research. 2010 Academic Article GET IT
Times cited: 255
Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms. American journal of hematology. 2010 Letter GET IT
Times cited: 21
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009 Academic Article GET IT
Times cited: 572
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia. 2009 Letter GET IT
Times cited: 218
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009 Academic Article GET IT
Times cited: 205
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009 Academic Article GET IT
Times cited: 347
Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annual review of medicine. 2009 Review GET IT
Times cited: 81
Warfarin-induced skin necrosis in a patient with heparin-induced thrombocytopenia: two diseases or one? 2008 GET IT
Times cited: 11
Functional evaluation of the grafted wall with porcine-derived small intestinal submucosa (SIS) to a stomach defect in rats. Surgery. 2007 Academic Article GET IT
Times cited: 17
An 87-year-old woman with respiratory distress and alveolar hemorrhage after transfusion. 2006 GET IT
Times cited: 6
Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion. 2006 Academic Article GET IT
Times cited: 287
Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion. 2006 Review GET IT
Times cited: 133
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. Molecular cancer therapeutics. 2006 Academic Article GET IT
Times cited: 39
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 47
Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses. The Journal of surgical research. 2005 Academic Article GET IT
Times cited: 20
In-transit melanoma: the role of alkylating-agent resistance in regional therapy. Journal of the American College of Surgeons. 2004 Academic Article GET IT
Times cited: 20
The role of hyperthermia in regional alkylating agent chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 29
Modulation of resistance to regional chemotherapy in the extremity melanoma model. Surgery. 2004 Academic Article GET IT
Times cited: 26
Immunotherapy of surgical malignancies. Current problems in surgery. 2004 Review GET IT
Times cited: 17
Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution. Cellular immunology. 2003 Academic Article GET IT

more ...

less ...

Background

education and training

M.D., Duke University School of Medicine 2004
B.Sc., Duke University 2000

Contact

full name

Omar Abdel-wahab

primary email

abdelwao@mskcc.org

VIVO Weill Cornell Medical College

Omar Abdel-wahab Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email